Law360, New York ( November 6, 2014, 10:27 AM EST) -- In the years since the U.S. Supreme Court's landmark KSR decision redefining the standard for invalidating a patent on obviousness grounds, life sciences companies have become accustomed to fighting an uphill battle in defending the validity of their so-called "secondary" or "follow on" patents in Hatch-Waxman litigation. These patents typically are not directed to an original drug compound but instead to new formulations, dose regimens or, in some cases, new indications for a known drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.